S1. Rituximab for ANCA-associated vasculitis: The experience in the United States
Authors:
- 1 April 2013
- journal article
- review article
- Published by Elsevier in La Presse Médicale
- Vol. 42 (4) , 530-532
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Rituximab for the treatment of Churg-Strauss syndrome with renal involvementNephrology Dialysis Transplantation, 2011
- Rituximab as Maintenance Therapy for Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisClinical Journal of the American Society of Nephrology, 2010
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisNew England Journal of Medicine, 2010
- Successful use of rituximab in a patient with Churg–Strauss syndrome and refractory central nervous system involvementAnnals of the Rheumatic Diseases, 2010
- Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 productionRheumatology, 2008
- Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndromeAnnals of the Rheumatic Diseases, 2006
- Update on rituximabAnnals of the Rheumatic Diseases, 2005
- Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody–associated vasculitisArthritis & Rheumatism, 2005
- Differential B- and T-cell activation in Wegener’s granulomatosisJournal of Allergy and Clinical Immunology, 1999
- Small-Vessel VasculitisNew England Journal of Medicine, 1997